The effect of the healthy lifestyle 'empowerment program' on care burden and adherence to health-promoting behaviours on mothers of children with type 1 diabetes.

Glob Public HealthApr 25, 2026 (epub)
Clinical ResearchEndocrinologyPediatrics

Behnaz Farahmandfard, Abolfazl Rahgoi, Mohammad Saatchi et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial assessed the Healthy Lifestyle Empowerment Program (HLEP) for mothers of children with type 1 diabetes (T1D) in Tehran. The study involved 64 mothers, revealing that HLEP significantly reduced care burden and improved adherence to health-promoting behaviors over 12 weeks. The intervention group showed a notable improvement in health-promoting behaviors (p = 0.027).

Key findings

  • The intervention group experienced a significant reduction in care burden immediately and 12 weeks post-HLEP (p = 0.311).
  • Health-promoting behaviors improved significantly in the intervention group over time (p = 0.027).
  • The control group showed increased care burden (p = 0.000) and decreased health-promoting behaviors (p = 0.017).

Why it matters

Mothers of children with T1D often face high care burdens, impacting their well-being. Effective interventions like HLEP can enhance their health-promoting behaviors and reduce stress, which is crucial for both caregivers and patients.

Source

PubMed · PMID 42033389

Published in Glob Public Health. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.